Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • AACR 2025

American Association for Cancer Research

April 25 - 30, 2025

  1. All
  2. Trastuzumab Deruxtecan
  3. Datopotamab Deruxtecan
  4. Durvalumab
  5. Osimertinib
  6. Savolitinib

PDF

An open-label, multicenter, Phase 2 study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors: DESTINY-PanTumor02

PDF

Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02) 

PPT

Trastuzumab Deruxtecan-Siena S, et al. Biomarker analysis DC-02 [Poster supplement].

PDF

Resistance to trastuzumab deruxtecan (T-DXd) in breast cancer via loss of HER2 expression and binding

PDF

Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and migration in viable human breast cancer slices

PDF

The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 Normalized Membrane Ratio

PDF

Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systems

PDF

Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC

PPT

Longitudinal circulating tumor DNA (ctDNA) analysis and acquired mechanisms of resistance to osimertinib (osi) in the China cohort of the FLAURA study

PDF

SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi

PDF

A phase I open-label positron-emission tomography study to determine brain exposure of [11C] savolitinib in healthy volunteers

PDF

An open-label, multicenter, Phase 2 study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors: DESTINY-PanTumor02

PDF

Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02) 

PPT

Trastuzumab Deruxtecan-Siena S, et al. Biomarker analysis DC-02 [Poster supplement].

PDF

Resistance to trastuzumab deruxtecan (T-DXd) in breast cancer via loss of HER2 expression and binding

PDF

Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and migration in viable human breast cancer slices

PDF

The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 Normalized Membrane Ratio

PDF

Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systems

PDF

Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC

PPT

Longitudinal circulating tumor DNA (ctDNA) analysis and acquired mechanisms of resistance to osimertinib (osi) in the China cohort of the FLAURA study

PDF

SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi

PDF

A phase I open-label positron-emission tomography study to determine brain exposure of [11C] savolitinib in healthy volunteers

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States